Amgen's Aimovig halved migraine days in 30 percent of trial patients

LOS ANGELES (Reuters) – A late-stage trial of Amgen Inc’s experimental drug Aimovig found that it reduced episodic migraines by at least half in 30 percent of patients who had failed up to four previous treatments, while 14 percent of placebo patients achieved that goal, the company said on Tuesday.

Source: Reuters Medical News

Leave a Reply

Your email address will not be published. Required fields are marked *